In the Monday afternoon session on alternative therapies in the management of inhibitors, Rebecca Kruse-Jarres discusses the latest developments in the use of porcine factor VIII.
Also Available In: English, Spanish This is not an official WFH translation. This resource has been translated with permission by
The development of inhibitory antibodies to therapeutic factor VIII (FVIII) in up to 40% of people with severe hemophilia A
In the Monday morning session entitled Inhibitors: Clinical Aspects, Jan Astermark described the different diagnostic assays laboratories can carry out